Keep in touch with meI'm using Intch to connect with new people. Use this link to open chat with me via Intch app
Work Background
GSD HealthClinical and Development Lead
Jan. 2022 - Dec. 2023Andorra
Adiuvo Investments S.ADelligent Technology Medical Franchise Head
Jan. 2017 - Apr. 2022Warsaw Area, PolandBusiness Development and Investment Management, Technology Scouting and Portfolio Build
Head of medical portfolio for an investment company founded in 2013 which finances, develops products and commercialises technologies related to wellness and personalised disease prevention
Technology scouting for lifestyle and behavioural health products, preventative medicine, wearable sensors and devices, disease management, enabling chaperone technology platforms, companion diagnostics and big data/algorythmisation
Management of technology scouting, commercial/scientific due diligence and business development for medical portfolio including set up commercial distributor network and exit strategy to large scale pharmaceutical and consumer health partners
a-connectIndependent Professional
Oct. 2013ZurichMultiple strategic planning, business development, therapeutic area strategy and business planning roles with top tier pharmaceutical and biotechnology companies
Future of Pharmaceutical R&D (reporting to Head of R&D and CSO/Innovation Head) - 4 months
Actionable roadmap to improve the ROI (e.g. IRR) from R&D by studying to top pharma companies to better understand the reasons for the decline in research productivity Identification of “best practices” within the Formula One framework and analysis of 30 years of sources of origination to assess M&A impact, buy/build, alternative sourcing models and collaboration frameworks
Rare Diseases New Business Venture (reporting to Head of R&D and CEO) - 2yrs
Development of a new Disease Therapy Area for entry into rare diseases market including:
Evaluation of the business opportunity as a sustainable strategic platform for the organisation, CHF100m financial case, including the impact of licensing and M&A
Considerations and principles for an organizational model (accelerated development and launch)
Development of an end-to-end operational model for a rare diseases business unit covering development, technical, medical, commercial, regulatory and partnering functions Therapeutic area strategy to provide framework for alliances and in-licensing for therapeutic franchises
Detailed guidelines for operating model including responsibilities for key activities to provide a baseline and global capability gap analysis, sequencing of resource hiring within headcount guidelines Global Policy for Patient Advocacy Group Engagement, Medical Communication - 3months
Building a new team to ensure that patient perspectives are reflected in the end-to-end asset lifecycle from Discovery to Established Products by assessing the key areas of patient interaction and information flow for enhanced collaboration Building an Engagement Framework with a blueprint for interaction with patients at all stages of the molecule lifecycle
SHILOH ADVISORS AGSenior Manager, Portfolio Screening and Due Diligence
Oct. 2011Zürich Area, SwitzerlandDevelopment of new Disruptive Innovation business unit to kick-start creative thinking and deliver new value within and beyond the core business to achieve business goal of €30bn from new products by 2020, including:
Creating on new idea generation techniques including a new ideation process and innovation tools to continuously generate ideas, develop them and fill the innovation pipeline Launch of a new innovation business unit supported by tailored governance structures and metrics (incl. development of a new innovation incubation unit, enhanced networking platform, building capability and skills for sustained growth, new innovation process for early stage ideas development)
Development of Technology Scouting unit to identify new technology assets to supplement portfolio, including technology trends tracking, development of technical scouting approach, due diligence on assets and integration into main portfolio post acquisition
Eden McCallumIndependent Consultant
Apr. 2010 - Dec. 2012Emerging Markets Commercial Excellence: Development of commercial excellence framework focusing on emerging markets and BRIC – including launch excellence model, key marketing excellence competencies and pricing strategy, sales resource efficiency and effectiveness
Emerging Markets Strategy and Operational Model: for emerging markets, including gap analysis and refinement of competency model, supporting account architecture, collaborative customer and national stakeholder network relationship model for rapid turnaround interventions
Oncology Business Restructure and Product Launch: Business optimisation for an international oncology portfolio to enable new oncology products to reach full market potential in European and emerging markets including product launch excellence framework and assessment of international market readiness E-Health Oncology Business Launch: assessing market readiness and building a technology platform application for key diseases (oncology home healthcare, women’s health, chronic pain management and Alzheimer’s disease) to engage on a healthcare professional, patient advocacy and end-consumer level
Tech Novia SolutionsManaging Director, Pharmaceutical Strategic Consulting, Business and Financial Analysis
Apr. 2009GlobalCEO of two technology start-ups, investment fund manager for medical portfolio of VC/PC
Senior roles with Roche, Biogen, Pfizer, GSK, Bayer, Eli Lilly, Sanofi and multiple biotech companies
Interim executive management roles, non-executive director positions on technology start ups
Strategic and financial consulting services predominantly with global biopharmaceutical companies, VC/PE corporations to support the market positioning and launch, valuation, technology transfer, trade sales bundling opportunities and launch via private and public markets of biopharmaceutical products
Emerging markets valuation including BRIC market potential of joint venture/alliances and business launch, market launch opportunities in the Asia-Pacific market for a hybrid investment/consulting group Transfer of technology assets, portfolio integration and launch of new assets in the US and European market, including: portfolio harmonisation, organisational structure and CSO strategy
Various business restructuring projects: organizational efficiency, global business alignment within matrix organisations, redesigning market-oriented and lean customer service processes and organisations
EdengeneAssociate Partner, Member of Management Team, Head of Life Sciences Practice
Aug. 2006 - Jun. 2010Led redesign of Edengene’s strategic foresight and visioning methodology
Lead Healthcare business including development of new business models for OTC healthcare companies, loyalty card extension for major UK healthcare company
Markets covered include biopharmaceuticals, medical devices, OTC, nutraceuticals, agribusiness,
Development of business model innovation framework and application to leading European pharmaco, providing innovation audit, global strategic vision, benefits case for innovation and executive mobilisation
Development of flexible strategy for European OTC company for global expansion, helping to reformulate market position, align core services to changing market demographics and innovate existing portfolio with a new channel-to-market strategy Interim Head of Consensus Business Group Solutions Advisory Business For 18 months, lead a joint consultant/PE project team as an integral member of the management team
Business development initiatives within European venture capital and private equity landscape, analysing investment portfolios, find reviews and financing philosophy to identify potential joint venture opportunities
Designed, launched and interim managed CBG Advisory Solutions business providing integrated strategic and technical bespoke low finance solutions
Gemini Consulting PartnersPrincipal, Head of Global Life Sciences Strategic Research
Oct. 1998 - Oct. 2004Design, research and implementation of $500m international investment vehicle for a leading pharmaceutical company to fund development in emerging healthcare markets and “hotspot” technologies, benchmarked against global venture capital and corporate funds including valuation model Redesign of entire financial and strategic planning process following the merger of two of the world’s largest pharmaceutical companies including scenario evaluation for portfolio management and capex planning
Lifecycle management for two of the world’s leading neurological products, supporting reorganisation of brand teams rolled out to all major country affiliates Head of Global Life Sciences Strategic Research Group Developed and launched the global life sciences Strategic Research Group, 25-person international strategic research and analysis team supporting global LS business unit (2K+ pharmaceutical & healthcare consultants)
Provided strategic resources to support major strategy projects, subject matter expert on key global projects
Managed global research publications strategy (quarterly publication: Perspectives on Life Sciences) focusing on major trends in the pharmaceutical, biotechnology and medical devices industries distributed)
Salomon Smith Barney Holdings Inc. (NYSE: SB)Senior Financial Analyst, Pharmaceutical and Healthcare Franchise Team, M&A Advisory
Oct. 1996 - Sep. 1998Experience in M&A strategic advisory, equity and equity-linked work, including extensive range of valuation tools (public market comparables, precedent transactions, relative/intrinsic valuation, DCF and WACC analysis) and creation of proprietary equity valuation models
Competitive analysis of wound care and surgical products market to evaluate the potential strategic and financial suitability of target company in a buy-side auction for a US healthcare company
Analysis of client’s biotechnology equity holdings and potential investment lifecycles, identification of implied cost of capital and evaluation of potential monetisation strategies for a Swiss pharmaceutical company
Evaluation of client suitability for potential IPO, shareholder and DD for a German pharmaceutical company
DataMonitorSenior Consultant, Life Scienes Strategy and Regional Lead, France
Sep. 1994 - Sep. 1996Lead Datamonitor’s French market presence and the development and launch of the Informatics practice Designing and developing an industry framework to evaluate start-up information technology companies and identify seeding opportunities for a US venture capital group
Leading a major investment-focused project to identify industry synergies between the pharmaceutical and informatics industries developing M&A benchmarks for a global tech group
Brown ShipleyBusiness Analyst, Corporate Accounts
Sep. 1993 - Sep. 1994Corporate business development with responsibility for developing and implementing sustainable market strategies for the department
Managing and developing selected intellectual property risks for the large-cap corporate portfolio
Intch is a Professional Networking App for the Future of WorkSee more people like Suzanne on Intch
300k+ people
130+ countries
AI matching
Get Intch if you'd like to
392444 people
24
Founder @ Bentley Mills
25
Director @ Circadian Global Forwarding Ltd
19
Project manager @ Zois Energy limited
64306 people
19
Project manager @ Zois Energy limited
18
Financial Consultant @ Standard capital corporation
43
Investments Relations Manager @ ExxonMobil